Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10740670 | 0.97 | LMNA (0.39) | TSHRLMNAKDM4EHTTATM | |
| SCHEMBL2796856 | 0.97 | LMNA (0.39) | TSHRLMNAKDM4EHTTATM | |
| SCHEMBL5720694 | 0.97 | LMNA (0.39) | TSHRLMNAKDM4EHTTATM | |
| SCHEMBL17793402 | 0.89 | — | — | |
| SCHEMBL494045 | 0.87 | LMNA (0.39) | TSHRLMNAKDM4EALDH1A1HTT | |
| SCHEMBL19200430 | 0.84 | HSD11B1 (0.37) | — | |
| SCHEMBL4978558 | 0.80 | LMNA (0.33) | TSHRLMNAKDM4EALDH1A1TP53 | |
| SCHEMBL29700485 | 0.80 | LMNA (0.31) | TSHRLMNA | |
| SCHEMBL2772714 | 0.78 | NEK2 (0.33) | — | |
| SCHEMBL13280344 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-7259135-B2 | Use of hexenal derivatives as perfumes | KAO CORPORATION (JP) | 2007-08-21 | — | — | US | claimed |
| EP-0418190-A2 | Use of 1-oxaspiro[4.4]nonan-2-on as a perfuming agent | Dragoco Gerberding & Co. GmbH (DE) | 1991-03-20 | — | — | EP | claimed |
| JP-3237198-A | — | — | None | — | — | JP | disclosed |
| JP-3237198-A | — | — | None | — | — | JP | disclosed |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2025-07-29 | — | — | US | disclosed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | US | disclosed |
| CN-112805063-B | Bicyclic derivatives as modulators of the GABAA A5 receptor | 吉瑞工厂 | 2024-02-23 | — | — | CN | disclosed |
| EP-0636116-B1 | PENTENE DERIVATIVES, THEIR PREPARATION AND THEIR USE | HENKEL KGAA (DE) | 1997-08-13 | — | — | EP | disclosed |
| WO-1997017314-A1 | CARBONYL COMPOUNDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1997-05-15 | — | — | WO | disclosed |
| US-5504066-A | FRAGRANCES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1996-04-02 | — | — | US | disclosed |
| EP-0586442-B1 | USE OF ISOMERIC 1,1,1-TRIALKYL-2-PHENYLETHANE DERIVATIVES AS ODORIFEROUS SUBSTANCES, AND FRAGRANCES CONTAINING THESE SUBSTANCES | HENKEL KGAA (DE) | 1995-01-04 | — | — | EP | disclosed |
| JP-H03237198-A | USE OF 1-OXASPIRO-(4,4)-NONAN-2-ONE AS PERFUME | DRAGOCO GERBERDING CO GMBH | 1991-10-23 | — | — | JP | disclosed |
| JP-H03237198-A | USE OF 1-OXASPIRO-(4,4)-NONAN-2-ONE AS PERFUME | DRAGOCO GERBERDING CO GMBH | 1991-10-23 | — | — | JP | disclosed |
| EP-0418190-A2 | Use of 1-oxaspiro[4.4]nonan-2-on as a perfuming agent | Dragoco Gerberding & Co. GmbH (DE) | 1991-03-20 | — | — | EP | disclosed |
| EP-0418190-A2 | Use of 1-oxaspiro[4.4]nonan-2-on as a perfuming agent | Dragoco Gerberding & Co. GmbH (DE) | 1991-03-20 | — | — | EP | disclosed |
| EP-0418190-A2 | Use of 1-oxaspiro[4.4]nonan-2-on as a perfuming agent | Dragoco Gerberding & Co. GmbH (DE) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | GABRA5, GABRA1, GABRB1 | TSHR 597/4885LMNA 2170/4885KDM4E 3842/4885 |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | GLRB, SRR, HCAR3 | TSHR 109/4885LMNA 2698/4885KDM4E 3241/4885 |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | ACSL3, ADSL, ACSL6 | TSHR 3603/4885LMNA 4443/4885KDM4E 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.